Lowest Price Guaranteed From USD 4,799
Published
March 2022
Pages
405
View Count
17725
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The companion diagnostics development services market is estimated to be worth $664 million in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 10.7% during the forecast period. Over the past few years, the improved understanding of molecular mechanisms involved in disease pathogenesis has resulted in the development of several targeted therapies. These therapies are tailored to target specific disease-related molecular signatures and require appropriate companion diagnostics (CDx) in order to make physicians aware of patients’ unique genetic profiles, enabling them to make informed treatment related decisions. These tests are most often developed parallel to an investigational drug in order to identify the latter’s safety and efficacy and measure its therapeutic effect on the target. With the approval of trastuzumab and HercepTest™ (an IHC-based companion diagnostic assay designed for determination of HER2 overexpression) by the USFDA in 1998, several novel targeted cancer drugs guided by a diagnostic assay, have progressed into clinical stages or are approved for commercial use. In fact, since 2020, a total of 44 companion diagnostics have been approved by the USFDA. Further, a study of nearly 200 unique pharmacological interventions evaluated across more than 670 clinical trials, suggests that the likelihood of a lead compound passing through various phases of clinical development and eventually getting approved is only 11%. The use of disease-specific biomarker information to recruit patients not only increases the success rates of the studies, but also reduces the trial costs by nearly 60%.
Given the various benefits, the healthcare industry is gradually shifting from the conventional, one-drug-for-all, paradigm to using tailored pharmacological interventions, which is expected to increase the need for companion diagnostics as well. However, given the complexities involved in the co-development of a drug and the affiliated companion diagnostic test, drug developers have demonstrated the preference to outsource the diagnostics development operations. In fact, around 80% of the companies are known to rely on third-party service providers for companion diagnostics development, primarily owing to the lack of in-house expertise for the development of these tests. As a result, many companies have made heavy investments in order to install robust tools and technologies, such as polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), next generation sequencing (NGS) and offer end-to-end services to sponsor companies engaged in this domain. In addition to conventional analytical techniques, several innovators have made latest upgrades in their portfolio by installing novel solutions, including digital PCR (dPCR) and digital immunoassay, in order to cater to the evolving needs of their customers. Given the growing demand for personalized therapies and ongoing innovations in technologies, we are led to believe that the opportunity for companion diagnostic developers / service providers is likely to witness a sustained growth over the coming years.
Several recent developments have taken place in the field of companion diagnostics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Companion Diagnostics Development Services Market (2nd Edition): Distribution by Type of Service Offered (Feasibility Studies, Assay Development, Analytical Validation, Clinical Validation and Manufacturing), Analytical Technique Used (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry / in situ Hybridization (IHC / ISH), Liquid Biopsy and Others), Therapeutic Areas (Oncological and Non-oncological) and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape, offering an informed opinion on the likely outsourcing of diagnostic development and manufacturing operations during 2022-2035. It features an in-depth analysis, highlighting the capabilities of various stakeholders involved in the companion diagnostics development value chain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across key services offered (feasibility studies, assay development, analytical validation, clinical validation and manufacturing), analytical techniques used (NGS, PCR, IHC-ISH, liquid biopsy and Others), therapeutic areas (oncological and non-oncological), and key geographical locations (North America, Europe and Asia- Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were influenced by discussions held with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:
Contents
Chapter 2 is an executive summary of the insights captured in our research. It offers a high- level view on the likely evolution of the companion diagnostics services market in the mid to long term.
Chapter 3 is an introductory chapter that highlights the importance of companion diagnostics in relation to personalized medicine. The chapter describes the approaches used to develop a companion diagnostic, along with information on various analytical techniques that form the basis for such tests. In addition, the chapter highlights the key considerations while selecting a contract diagnostics partner (CDO), along with key market drivers and challenges associated with outsourcing the development and manufacturing of companion diagnostics.
Chapter 4 provides an overview of the companion diagnostics services market, including information on 150 players offering contract services for one or multiple steps involved in the development and manufacturing of companion diagnostics. It features an in-depth analysis of the industry players, based on a number of parameters, such as year of establishment, company size, ownership, geographical location of headquarters, companion diagnostics-related service portfolio (biomarker discovery / identification, biomarker development, assay development, feasibility studies, analytical validation, clinical validation, regulatory assistance, commercialization, manufacturing and other supporting services), analytical techniques used (enzyme-linked immune sorbent assay (ELISA), flow cytometry, in situ hybridization (ISH), immunohistochemistry (IHC), microarray, next generation sequencing (NGS), polymerase chain reaction (PCR), sanger sequencing and spectroscopy), and regulatory certification / accreditation (College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and International Organization for Standardization (ISO)).
Chapter 5 provides an insightful competitiveness analysis of the companion diagnostics development service providers based in North America, Europe and Asia- Pacific and Rest of the World. The analysis compares the capabilities of companies on the basis of their supplier strength (in terms of experience and company size) and service portfolio strength (in terms of number of services offered, number of analytical techniques used, therapeutic areas assessed, and number of precision medicine related deals signed since 2017).
Chapter 6 includes detailed profiles the key players offering companion diagnostics development services. Each company profile features a brief overview of the company, its financial information (if available), information on its companion diagnostics-related service portfolio, recent developments, and an informed future outlook.
Chapter 7 provides a list of companion diagnostics along with information on their commercial availability (approved / investigational), assay technique used (enzyme-linked immune sorbent assay (ELISA), flow cytometry, in situ hybridization (ISH), immunohistochemistry (IHC), micro array, next generation sequencing (NGS), polymerase chain reaction (PCR), sanger sequencing and spectroscopy), target disease indications, therapeutic areas (oncological disorders, infectious diseases, metabolic disorders, neurological disorders, inflammatory disorders and others), type of sample analyzed (tumor tissue, blood, bone marrow and saliva), type of biomarker detected (alteration(s) in ALK, BCR, BRAF, BRCA, ErbB, MET, MSI / dMMR, NTRK, PD-L1, RAS, PGR, ROS and PIK3CA), chemical nature of biomarker (gene and protein), regulatory certification / accreditation (FDA PMA, CE Mark, MHLW, PMDA, NMPA and others) and expediated review designation (for marketed products), and year of initiation of development (for investigational programs). It also provides details on the developers, highlighting their year of establishment, company size, ownership and geographical location of their headquarters.
Chapter 8 presents an analysis of the partnerships and collaborations for companion diagnostics services established during 2017- 2021, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, analytical technique used, geographical location of involved companies and the most active players.
Chapter 9 features a list of 300+ stakeholders that are anticipated to partner with companion diagnostics services providers in the foreseen future. The players have been shortlisted based on a detailed analysis of relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products.
Chapter 10 presents insights from a detailed analysis of the mergers and acquisitions reported in this domain, during the period 2017- 2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year of agreement, type of deal, geographical location, size and ownership of the companies involved, key value drivers, and acquisition deal multiples (based on revenues).
Chapter 11 provides a qualitative assessment of the current and long-term needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain. In addition, it highlights key areas of concerns associated with this industry, along with our opinion (based on past and prevalent trends) on how the industry is anticipated to address them over the coming years.
Chapter 12 presents a value chain analysis featuring a discussion on various steps of the companion diagnostics development operations, namely R&D, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities, as well as the cost requirements across each of the aforementioned stages.
Chapter 13 provides a detailed clinical trial analysis of completed, ongoing and planned biomarker-driven oncology clinical trials sponsored by prominent big pharmaceutical companies, in the last five years. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial registration year, phase of development, trial sponsors, recruitment status, therapy design, enrolled patient population, popularity of biomarkers, and popularity of target indications.
Chapter 14 is a case study presenting a list of therapies currently in use with companion diagnostics, providing information on their commercial availability, type of molecule, route of administration, and number of corresponding companion diagnostics products / programs. In addition, it provides details on drug developers, including information on their year of establishment, company size, ownership and geographical location of their headquarters.
Chapter 15 is a case study focused on the current market landscape of precision medicine software solutions that offer intelligent insights to facilitate informed decision making to different stakeholders in this industry. It presents a list of software solutions, along with information on the type of platform utilized, purpose of software solution, type of data processed, therapeutic area, and types of end users. In addition, it presents a list of developers of software solutions, along with analysis on their year of establishment, company size, ownership and geographical location of headquarters.
Chapter 16 presents an insightful market forecast analysis, highlighting the future potential of the companion diagnostics development and manufacturing services market, till 2035. We have segregated the opportunity of the market on the basis of Type of Service Offered (Feasibility Studies, Assay Development, Analytical Validation, Clinical Validation and Manufacturing), Analytical Techniques Used (NGS, PCR, IHC / ISH, Liquid Biopsy and Others), Therapeutic Areas (Oncological and Non-oncological Disorders), and Key Geographies (North America, Europe, Asia- Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022- 2035.
Chapter 17 summarizes the entire report, highlighting various facts related to contemporary market trend and the likely evolution of the companion diagnostics development services market.
Chapter 18 is a collection of interview transcripts of the discussions held with stakeholders in this market. In this chapter, we have presented the details of interviews held with Mike Klein, (Chief Executive Officer, Genomenon), Mark Kiel (Founder and Chief Scientific Officer, Genomenon), Candace Chapman (Vice President of Marketing, Genomenon), Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations), Paul Kortschak (Former Senior Vice President, Novodiax), Pablo Ortiz (Chief Executive Officer, OWL Metabolomics) and Lawrence M. Weiss (Former Chief Scientific Officer, NeoGenomics Laboratories).
Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 20 is an appendix, which provides a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Personalized Medicines
3.3. Overview of Companion Diagnostics
3.3.1. Development of Companion Diagnostics
3.3.2. Analytical Techniques Used in Companion Diagnostic Tests
3.3.2.1. Immunohistochemistry
3.3.2.2. In situ Hybridization
3.3.2.3. Polymerase Chain Reaction (PCR)
3.3.2.4. DNA Sequencing / Next Generation Sequencing
3.3.2.5. Liquid Biopsy
3.3.2.6. Flow Cytometry
3.3.3. Advantages of Companion Diagnostics
3.4. Applications of Companion Diagnostics across Different Therapeutic Areas
3.4.1. Oncology
3.4.2. Infectious Diseases
3.4.3. Neurological Disorders
3.5. Regulatory Review and Approval Process for Companion Diagnostics
3.6. Existing Challenges
3.7. Key Guidelines for Selecting a Contract Diagnostics Organization (CDO)
3.8. Future Perspectives
4. COMPANION DIAGNOSTICS SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Companion Diagnostics Service Providers: List of Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Company Ownership
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Other Affiliated Services Offered
4.2.7. Analysis by Type of Analytical Technique Used
4.2.8. Analysis by Therapeutic Area
4.2.9. Grid Representation: Analysis by Company Size, Location of Headquarters and Type of Service Offered
4.2.10. Grid Representation: Analysis by Company Size, Location of Headquarters and Type of Analytical Technique Used
4.2.11. Analysis by Regulatory Accreditation / Certification
5. COMPANION DIAGNOSTICS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Methodology
5.3 Assumptions / Key Parameters
5.4 Competitiveness Analysis: Companion Diagnostics Service Providers
5.4.1 Companion Diagnostics Service Providers based in North America
5.4.2 Companion Diagnostics Service Providers based in Europe
5.4.3 Companion Diagnostics Service Providers based in Asia-Pacific and Rest of the World
5.5. Summary of Key Players
6. COMPANION DIAGNOSTICS SERVICE PROVIDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Key Players in North America
6.2.1. Geneuity Clinical Research Services
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Interpace Biosciences
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Financial Information
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Labcorp (formerly known as Covance)
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Financial Information
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Quest Diagnostics
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Financial Information
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Q² Solutions
6.2.5.1. Company Overview
6.2.5.2. Service Portfolio
6.2.5.3. Financial Information
6.2.5.4. Recent Developments and Future Outlook
6.2.6. ResearchDx
6.2.6.1. Company Overview
6.2.6.2. Service Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.3. Key Players in Europe
6.3.1. Almac Diagnostic Services
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Financial Information
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Biocartis
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Financial Information
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Cerba Research
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Eurofins
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Financial Information
6.3.4.4. Recent Developments and Future Outlook
6.3.5. MLM Medical Labs
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.3.6. QIAGEN
6.3.6.1. Company Overview
6.3.6.2. Service Portfolio
6.3.6.3. Financial Information
6.3.6.4. Recent Developments and Future Outlook
6.4. Key Players in Asia-Pacific and Rest of the World
6.4.1. BGI Genomics
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
6.4.3. MEDICAL & BIOLOGICAL LABORATORIES (MBL)
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Recent Developments and Future Outlook
6.4.4. Novogene
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Recent Developments and Future Outlook
7. COMPANION DIAGNOSTICS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Companion Diagnostics: List of Marketed Products / Investigational Programs
7.2.1. Analysis by Assay Technique Used
7.2.2. Analysis by Target Disease Indication
7.2.3. Analysis by Therapeutic Area
7.2.4. Analysis by Type of Biomarker Detected
7.2.5. Analysis by Chemical Nature of Biomarker
7.2.6. Analysis by Type of Sample Used
7.2.7. Analysis by Commercial Availability and Therapeutic Area
7.2.8. Investigational Programs: Analysis by Year of Initiation of Development
7.2.9. Marketed Products: Analysis by Year of Approval
7.2.10. Marketed Products: Analysis by Regulatory Authority Involved
7.2.11. Marketed Products: Analysis by Year of Approval and Regulatory Authority Involved
7.2.12. Marketed Products: Analysis by Expediated Review Designation and Type of Biomarker
7.2.13. Heat Map Representation: Analysis by Target Disease Indication and Assay Technique Used
7.3. Companion Diagnostic Devices: List of Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Company Ownership
7.3.4. Analysis by Location of Headquarters
7.3.5. Most Active Players: Analysis by Number of Marketed Products and Investigational Programs
7.3.6. Most Active Players: Analysis by Number of Marketed Products
7.3.7. Most Active Players: Analysis by Number of Target Disease Indications
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Year of Partnership and Type of Partner
8.3.5. Analysis by Type of Partnership and Type of Partner
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.9. Intercontinental and Intracontinental Agreements
9. LIKELY PARTNER ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Likely Partners for Companion Diagnostics Service Providers: Alzheimer’s Disease
9.4.1. Potential Strategic Partners for Initiatives on Amyloid Beta Biomarker
9.4.1.1. Companies Working on the Amyloid Beta Biomarker
9.4.1.2. World Map Representation: Amyloid Beta Biomarker Focused Clinical Trials
9.4.2. Potential Strategic Partners for Initiatives on Tau Biomarker
9.4.2.1. Companies Working on the Tau Biomarker
9.4.2.2. World Map Representation: Tau Biomarker Focused Clinical Trials
9.5. Likely Partners for Companion Diagnostics Service Providers: Breast Cancer
9.5.1. Potential Strategic Partners for Initiatives on BRCA Biomarker
9.5.1.1. Companies Working on the BRCA Biomarker
9.5.1.2. World Map Representation: BRCA Biomarker Focused Clinical Trials
9.5.2. Potential Strategic Partners for Initiatives on HER Biomarker
9.5.2.1. Companies Working on the HER Biomarker
9.5.2.2. World Map Representation: HER Biomarker Focused Clinical Trials
9.5.3. Potential Strategic Partners for Initiatives on HR Biomarker
9.5.3.1. Companies Working on the HR Biomarker
9.5.3.2. World Map Representation: HR Biomarker Focused Clinical Trials
9.5.4. Potential Strategic Partners for Initiatives on PD-L1 Biomarker
9.5.4.1. Companies Working on the PD-L1 Biomarker
9.5.4.2. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
9.6. Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer
9.6.1. Potential Strategic Partners for Initiatives on BRAF Biomarker
9.6.1.1. Companies Working on the BRAF Biomarker
9.6.1.2. World Map Representation: BRAF Biomarker Focused Clinical Trials
9.6.2. Potential Strategic Partners for Initiatives on EGFR Biomarker
9.6.2.1. Companies Working on the EGFR Biomarker
9.6.2.2. World Map Representation: EGFR Biomarker Focused Clinical Trials
9.6.3. Potential Strategic Partners for Initiatives on KRAS Biomarker
9.6.3.1. Companies Working on the KRAS Biomarker
9.6.3.2. World Map Representation: KRAS Biomarker Focused Clinical Trials
9.6.4. Potential Strategic Partners for Initiatives on MSI Biomarker
9.6.4.1. Companies Working on the MSI Biomarker
9.6.4.2. World Map Representation: MSI Biomarker Focused Clinical Trials
9.6.5. Potential Strategic Partners for Initiatives on NRAS Biomarker
9.6.5.1. Companies Working on the NRAS Biomarker
9.6.5.2. World Map Representation: NRAS Biomarker Focused Clinical Trials
9.7. Likely Partners for Companion Diagnostic Service Providers: HIV
9.7.1. Potential Strategic Partners for Initiatives on CCR5 Biomarker
9.7.1.1. Companies Working on the CCR5 Biomarker
9.7.1.2. World Map Representation: CCR5 Biomarker Focused Clinical Trials
9.8. Likely Partners for Companion Diagnostics Service Providers: Lung Cancer
9.8.1. Potential Strategic Partners for Initiatives on ALK Biomarker
9.8.1.1. Companies Working on the ALK Biomarker
9.8.1.2. World Map Representation: ALK Biomarker Focused Clinical Trials
9.8.2. Potential Strategic Partners for Initiatives on EGFR Biomarker
9.8.2.1. Companies Working on the EGFR Biomarker
9.8.2.2. World Map Representation: EGFR Biomarker Focused Clinical Trials
9.8.3. Potential Strategic Partners for Initiatives on PD-L1 Biomarker
9.8.3.1. Companies Working on the PD-L1 Biomarker
9.8.3.2. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
9.8.4. Potential Strategic Partners for Initiatives on RET Biomarker
9.8.4.1. Companies Working on the RET Biomarker
9.8.4.2. World Map Representation: RET Biomarker Focused Clinical Trials
9.8.5. Potential Strategic Partners for Initiatives on ROS Biomarker
9.8.5.1. Companies Working on the ROS Biomarker
9.8.5.2. World Map Representation: ROS Biomarker Focused Clinical Trials
9.9. Likely Partners for Companion Diagnostics Service Providers: NASH / NAFLD
9.9.1. Potential Strategic Partners for Initiatives on AST Biomarker
9.9.1.1. Companies Working on the AST Biomarker
9.9.1.2. World Map Representation: AST Biomarker Focused Clinical Trials
9.10. Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer
9.10.1. Potential Strategic Partners for Initiatives on BRCA Biomarker
9.10.1.1. Companies Working on the BRCA Biomarker
9.10.1.2. World Map Representation: BRCA Biomarker Focused Clinical Trials
9.10.2. Potential Strategic Partners for Initiatives on CA-125 Biomarker
9.10.2.1. Companies Working on the CA-125 Biomarker
9.10.2.2. World Map Representation: CA-125 Biomarker Focused Clinical Trials
9.11. Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer
9.11.1. Potential Strategic Partners for Initiatives on AR-V7 Biomarker
9.11.1.1. Companies Working on the AR-V7 Biomarker
9.11.1.2. World Map Representation: AR-V7 Biomarker Focused Clinical Trials
10. MERGERS AND ACQUISITONS
10.1. Chapter Overview
10.2. Merger and Acquisition Models
10.3. List of Mergers and Acquisitions
10.3.1. Analysis by Type of Deal
10.3.2. Analysis by Year of Deal
10.3.3. Regional Analysis
10.3.3.1. Continent-wise Distribution
10.3.3.2. Intercontinental and Intracontinental Deals
10.3.3.3. Country-wise Distribution
10.3.4. Analysis by Company Size
10.3.5. Ownership Change Matrix
10.3.6. Analysis by Key Value Drivers
10.3.7. Valuation Analysis: Acquisition Deal Multiples
10.3.8. Key Players: Analysis by Number of Deals
11. STAKEHOLDER NEEDS ANALYSIS
11.1. Chapter Overview
11.2. Companion Diagnostics: Needs of Different Stakeholders
11.3. Comparison of Needs of Various Stakeholders
11.3.1. Needs of Drug Developers
11.3.2. Needs of Companion Diagnostics Developers
11.3.3. Needs of Regulatory Authorities
11.3.4. Needs of Testing Laboratories
11.3.5. Needs of Payers / Insurance Providers
11.3.6. Needs of Physicians
11.3.7. Needs of Patients
12. VALUE CHAIN ANALYSIS
12.1. Chapter Overview
12.2. Companion Diagnostics Value Chain: Cost Distribution
12.2.1. Research and Product Development
12.2.2. Manufacturing and Assembly
12.2.3. Clinical Trials, FDA Approval and Other Administrative Tasks
12.2.4. Payer Negotiation and KOL Engagement
12.2.5. Marketing and Sales
12.3. Companion Diagnostics Development Operations: Key Cost Contributors
12.4. Companion Diagnostics Co-Development Operations: Key Cost Contributors
13. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA PERSPECTIVE
13.1. Chapter Overview
13.2. Methodology
13.3. Big Pharma Sponsored Biomarker Focused Clinical Trials: List of Likely Drug Candidates for IVD Developers
13.4. Clinical Trial Analysis
13.4.1. Analysis of Trials by Trial Registration Year
13.4.2. Analysis of Trials by Phase of Development
13.4.3. Analysis of Trials by Sponsor
13.4.4. Analysis of Trials by Recruitment Status
13.4.5. Analysis of Trials by Therapy Design
13.4.6. Analysis of Trials by Geography
13.4.7. Analysis of Trials by Enrolled Patient Population
13.4.8. Analysis of Trials by Popularity of Biomarkers
13.4.8.1. Most Popular Biomarkers
13.4.8.2. Moderately Popular Biomarkers
13.4.8.3. Less Popular / Preliminary Stage Biomarkers
13.4.8.4. Other Emerging Biomarkers: Word Cloud
13.4.8.5. Analysis of Trials of Most Popular Biomarkers by Trial Registration Year
13.4.8.6. Analysis of Trials of Moderately Popular Biomarkers by Trial Registration Year
13.4.8.7. Analysis of Trials of Less Popular Biomarkers by Trial Registration Year
13.4.8.8. Analysis of Trials of Most Popular Biomarkers by Phase of Development
13.4.8.9. Analysis of Trials of Moderately Popular Biomarkers by Phase of Development
13.4.8.10. Analysis of Trials of Less Popular and Other Biomarkers by Phase of Development
13.4.8.11. Analysis of Trials of Most Popular Biomarkers by Sponsors
13.4.8.12. Analysis of Trials of Moderately Popular Biomarkers by Sponsors
13.4.8.13. Analysis of Trials of Less Popular and Other Biomarkers by Sponsors
13.4.9. Analysis of Trials by Popularity of Indications
13.4.9.1. Most Popular Indications
13.4.9.2. Moderately Popular Indications
13.4.9.3 Less Popular and Other Indications
13.4.9.4. Other Emerging Indications: Word Cloud
13.4.9.5. Analysis of Trials of Most Popular Indications by Trial Registration Year
13.4.9.6. Analysis of Trials of Moderately Popular Indications by Trial Registration Year
13.4.9.7. Analysis of Trials of Less Popular / Preliminary Stage Indications by Trial Registration Year
13.4.9.8. Analysis of Trials of Most Popular Indications by Phase of Development
13.4.9.9. Analysis of Trials of Moderately Popular Indications by Phase of Development
13.4.9.10. Analysis of Trials of Less Popular / Preliminary Stage Indications by Phase of Development
13.4.9.11. Analysis of Trials of Less Popular / Preliminary Stage Indications by Trial Registration Year
13.4.9.12. Analysis of Trials of Most Popular Indications by Sponsor
13.4.9.13. Analysis of Trials of Moderately Popular Indications by Sponsor
13.4.9.14. Analysis of Trials of Less Popular / Preliminary Stage Indications by Sponsor
13.5. Clinical Trials Summary
14. CASE STUDY ON BIOMARKER-DRIVEN TARGETED THERAPIES IN USE WITH COMPANION DIAGNOSTICS
14.1. Chapter Overview
14.2. Biomarker-Driven Targeted Therapies: Pipeline Review
14.2.1. Analysis by Commercial Availability
14.2.2. Analysis by Type of Molecule
14.2.3. Analysis by Commercial Availability and Type of Molecule
14.2.4. Analysis by Route of Administration
14.2.5. Leading Biomarker-Driven Targeted Therapies: Analysis by Number of Companion Diagnostic Products / Programs
14.3. Biomarker-Driven Targeted Therapies: Developer Landscape
14.3.1. Analysis by Year of Establishment
14.3.2. Analysis by Company Size
14.3.3. Analysis by Company Ownership
14.3.4. Analysis by Location of Headquarters
14.3.5. Leading Players: Analysis by Number of Drugs
14.4. Heat Map Representation: Analysis by Company Size, Location of Headquarters and Commercial Availability of Drug
15. CASE STUDY ON PRECISION MEDICINE SOFTWARE SOLUTIONS
15.1. Chapter Overview
15.2. Precision Medicine Software Solutions: List of Products
15.2.1. Analysis by Type of Platform
15.2.2. Analysis by Purpose of Software Applications
15.2.3. Analysis by Type of Data Handled
15.2.4. Analysis by Therapeutic Area
15.2.5. Analysis by Type of End User
15.3. Precision Medicine Software Solutions: List of Developers
15.3.1. Analysis by Year of Establishment
15.3.2. Analysis by Company Size
15.3.3. Analysis by Location of Headquarters
16. COMPANION DIAGNOSTICS SERVICE PROVIDERS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
16.1 Chapter Overview
16.2. Key Assumptions and Forecast Methodology
16.3. Global Companion Diagnostics Services Market, 2022-2035
16.3.1. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2022-2035
16.3.2. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique Used, 2022-2035
16.3.3. Global Companion Diagnostics Services Market: Distribution by Therapeutic Area, 2022-2035
16.3.4. Global Companion Diagnostics Services Market: Distribution by Region, 2022-2035
16.4. Companion Diagnostics Services Market in North America, 2022-2035
16.4.1. Companion Diagnostics Services Market in North America: Distribution by Type of Service Offered, 2022-2035
16.4.2. Companion Diagnostics Services Market in North America: Distribution by Type of Analytical Technique Used, 2022-2035
16.4.3. Companion Diagnostics Services Market in North America: Distribution by Therapeutic Area, 2022-2035
16.5. Companion Diagnostics Services Market in Europe, 2022-2035
16.5.1. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2022-2035
16.5.2. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique Used, 2022-2035
16.5.3. Companion Diagnostics Services Market in Europe: Distribution by Therapeutic Area, 2022-2035
16.6. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World, 2022-2035
16.6.1. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Service Offered, 2022-2035
16.6.2. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Analytical Technique Used, 2022-2035
16.6.3. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Genomenon
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Mike Klein, Chief Executive Officer; Mark Kiel, Founder and Chief Scientific Officer; and Candace Chapman, Vice President of Marketing
17.3. Tymora Analytical Operations
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Anton Iliuk, President and Chief Technology Officer
17.4. Novodiax
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Paul Kortschak, Former Senior Vice President
17.5. OWL Metabolomics
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Pablo Ortiz, Chief Executive Officer
17.6. NeoGenomics Laboratories
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Lawrence M. Weiss, Former Chief Scientific Officer
18. CONCLUDING REMARKS
18.1. Chapter Overview
18.2. Key Takeaways
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Companion Diagnostics: Role in Clinical Trials
Figure 3.2 Advantages of Companion Diagnostics
Figure 3.3 Failure Rates: Distribution by Type of Drug Class
Figure 3.4 Challenges Associated with the Development of Companion Diagnostics
Figure 3.5 Key Considerations for Selecting a CDO Partner
Figure 4.1 Companion Diagnostics Service Providers: Distribution by Year of Establishment
Figure 4.2 Companion Diagnostics Service Providers: Distribution by Company Size
Figure 4.3 Companion Diagnostics Service Providers: Distribution by Company Ownership
Figure 4.4 Companion Diagnostics Service Providers: Distribution by Location of Headquarters
Figure 4.5 World Map Representation: Analysis by Geography
Figure 4.6 Companion Diagnostics Service Providers: Distribution by Type of Service Offered
Figure 4.7 Companion Diagnostics Service Providers: Distribution by Other Affiliated Services Offered
Figure 4.8 Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique Used
Figure 4.9 Companion Diagnostics Service Providers: Distribution by Therapeutic Area
Figure 4.10 Grid Representation: Distribution by Company Size, Location of Headquarters and Type of Service Offered
Figure 4.11 Grid Representation: Distribution by Company Size, Location of Headquarters and Analytical Technique Used
Figure 4.12 Companion Diagnostics Service Providers: Distribution by Regulatory Accreditation / Certification
Figure 5.1 Competitiveness Analysis: Companion Diagnostics Service Providers in North America
Figure 5.2 Competitiveness Analysis: Companion Diagnostics Service Providers in Europe
Figure 5.3 Competitiveness Analysis: Companion Diagnostics Service Providers in Asia-Pacific and Rest of the World
Figure 5.4 Competitiveness Analysis of Companion Diagnostics Service Providers: Competitiveness Score of Top Service Providers
Figure 6.1 Interpace Biosciences: Annual Revenues, FY 2016-Q3 2021 (USD Million)
Figure 6.2 Labcorp Drug Development: Annual Revenues, FY 2016-2021 (USD Billion)
Figure 6.3 Quest Diagnostics: Annual Revenues, FY 2016-2021 (USD Billion)
Figure 6.4 Q² Solutions: Annual Revenues, FY 2016-2021 (USD Million)
Figure 6.5 Almac Group Diagnostics: Annual Revenues, FY 2016-2021 (GBP Million)
Figure 6.6 Biocartis: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Figure 6.7 Eurofins: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Figure 6.8 QIAGEN: Annual Revenues, FY 2016-2021 (USD Billion)
Figure 7.1 Companion Diagnostics: Distribution by Assay Technique Used
Figure 7.23 Companion Diagnostics: Distribution by Target Disease Indication
Figure 7.3 Companion Diagnostics: Distribution by Therapeutic Area
Figure 7.4 Companion Diagnostics: Distribution by Type of Biomarker Detected
Figure 7.5 Companion Diagnostics: Distribution by Chemical Nature of Biomarker
Figure 7.6 Companion Diagnostics: Distribution by Type of Sample Used
Figure 7.7 Companion Diagnostics: Distribution by Commercial Availability and Therapeutic Area
Figure 7.8 Companion Diagnostics: Distribution by Year of Initiation of Development of Investigational Programs
Figure 7.9 Companion Diagnostics: Distribution by Year of Approval of Marketed Products
Figure 7.10 Companion Diagnostics: Distribution by Regulatory Authority Involved in the Approval of Marketed Products
Figure 7.11 Companion Diagnostics: Distribution by Expediated Review Designation and Type of Biomarker
Figure 7.12 Heat Map Representation: Distribution by Assay Technique Used and Target Disease Indication
Figure 7.13 Companion Diagnostics Developers: Distribution by Year of Establishment
Figure 7.14 Companion Diagnostics Developers: Distribution by Company Size
Figure 7.15 Companion Diagnostics Developers: Distribution by Company Ownership
Figure 7.16 Companion Diagnostics Developers: Distribution by Location of Headquarters
Figure 7.17 World Map Representation: Distribution by Geography
Figure 7.18 Most Active Players: Distribution by Number of Marketed Products and Investigational Programs
Figure 7.19 Most Active Players: Distribution by Number of Marketed Products
Figure 7.20 Most Active Players: Distribution by Number of Target Disease Indications
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.7 Most Active Players: Distribution by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Regional Distribution
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 World Map Representation: Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials
Figure 9.2 World Map Representation: Regional Distribution of Tau Biomarker Focused Clinical Trials
Figure 9.3 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Figure 9.4 World Map Representation: Regional Distribution of HER Biomarker Focused Clinical Trials
Figure 9.5 World Map Representation: Regional Distribution of HR Biomarker Focused Clinical Trials
Figure 9.6 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Figure 9.7 World Map Representation: Regional Distribution of BRAF Biomarker Focused Clinical Trials
Figure 9.8 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Figure 9.9 World Map Representation: Regional Distribution of KRAS Biomarker Focused Clinical Trials
Figure 9.10 World Map Representation: Regional Distribution of MSI Biomarker Focused Clinical Trials
Figure 9.11 World Map Representation: Regional Distribution of NRAS Biomarker Focused Clinical Trials
Figure 9.12 World Map Representation: Regional Distribution of CCR5 Biomarker Focused Clinical Trials
Figure 9.13 World Map Representation: Regional Distribution of ALK Biomarker Focused Clinical Trials
Figure 9.14 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Figure 9.15 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Figure 9.16 World Map Representation: Regional Distribution of RET Biomarker Focused Clinical Trials
Figure 9.17 World Map Representation: Regional Distribution of ROS Biomarker Focused Clinical Trials
Figure 9.18 World Map Representation: Regional Distribution of AST Biomarker Focused Clinical Trials
Figure 9.19 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Figure 9.20 World Map Representation: Regional Distribution of CA-125 Biomarker Focused Clinical Trials
Figure 9.21 World Map Representation: Regional Distribution of AR-V7 Biomarker Focused Clinical Trials
Figure 10.1 Mergers and Acquisitions: Distribution by Type of Deal
Figure 10.2 Mergers and Acquisitions: Distribution by Year of Deal
Figure 10.3 Mergers and Acquisitions: Regional Distribution
Figure 10.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 10.5 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 10.6 Mergers and Acquisitions: Country-wise Distribution
Figure 10.7 Mergers and Acquisitions: Distribution by Company Size
Figure 10.8 Mergers and Acquisitions: Ownership Change Matrix
Figure 10.9 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 10.10 Mergers and Acquisitions: Valuation by Acquisition Deal Multiples
Figure 10.11 Key Players: Distribution by Number of Deals
Figure 11.1 Companion Diagnostics: Stakeholder Needs
Figure 11.2 Comparison of Needs of a Drug Developer
Figure 11.3 Comparison of Needs of a Companion Diagnostic Developer
Figure 11.4 Comparison of Needs of a Regulatory Authorities
Figure 11.5 Comparison of Needs of Testing Laboratories
Figure 11.6 Comparison of Needs of Payers / Insurance Providers
Figure 11.7 Comparison of Needs of Physicians
Figure 11.8 Comparison of Needs of Patients
Figure 12.1 Companion Diagnostics Value Chain: Cost Distribution
Figure 12.2 Cost Distribution Across the Companion Diagnostics Value Chain
Figure 12.3 Costs Associated with Research and Product Development
Figure 12.4 Costs Associated with Manufacturing and Assembly
Figure 12.5 Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 12.6 Costs Associated with Payer Negotiation and KOL Engagement
Figure 12.7 Costs Associated with Marketing and Sales
Figure 13.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 13.2 Clinical Trial Analysis: Distribution by Phase of Development
Figure 13.3 Clinical Trial Analysis: Distribution by Sponsor
Figure 13.4 Clinical Trial Analysis: Distribution by Recruitment Status
Figure 13.5 Clinical Trial Analysis: Distribution by Therapy Design
Figure 13.6 Clinical Trial Analysis: Distribution by Geography
Figure 13.7 Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 13.8 Clinical Trial Analysis: Distribution by Most Popular Biomarkers
Figure 13.9 Clinical Trial Analysis: Distribution by Moderately Popular Biomarkers
Figure 13.10 Clinical Trial Analysis: Distribution by Less Popular / Preliminary Stage Biomarkers
Figure 13.11 Other Emerging Biomarkers: Word Cloud
Figure 13.12 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Trial Registration Year
Figure 13.13 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Trial Registration Year
Figure 13.14 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Trial Registration Year
Figure 13.15 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Phase of Development
Figure 13.16 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Phase of Development
Figure 13.17 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Phase of Development
Figure 13.18 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Sponsors
Figure 13.19 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Sponsors
Figure 13.20 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Sponsors
Figure 13.21 Clinical Trial Analysis: Distribution of Trials for Most Popular Indications
Figure 13.22 Clinical Trial Analysis: Distribution of Trials for Moderately Popular Indications
Figure 13.23 Clinical Trial Analysis: Distribution of Trials for Less Popular and Other Indications
Figure 13.24 Other Emerging Indications: Word Cloud
Figure 13.25 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Trial Registration Year
Figure 13.26 Clinical Trial Analysis: Distribution of Trial of Moderately Popular Indications by Trial Registration Year
Figure 13.27 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Indications by Trial Registration Year
Figure 13.28 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Phase of Development
Figure 13.29 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Phase of Development
Figure 13.30 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Phase of Development
Figure 13.31 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Sponsor
Figure 13.32 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Sponsor
Figure 13.33 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Sponsor
Figure 13.34 Clinical Trial Analysis: Distribution of Trials of Lung Cancer by Affiliated Biomarkers
Figure 13.35 Clinical Trials Summary: Distribution of Trials of Breast Cancer by Affiliated Biomarkers
Figure 13.36 Clinical Trials Summary: Distribution of Trials of Lymphoma by Affiliated Biomarkers
Figure 13.37 Clinical Trials Summary: Distribution of Trials of Ovarian Cancer by Affiliated Biomarkers
Figure 13.38 Clinical Trials Summary: Distribution of Trials of Prostate Cancer by Affiliated Biomarkers
Figure 13.39 Clinical Trials Summary: Distribution of Trials of Melanoma by Affiliated Biomarkers
Figure 13.40 Clinical Trials Summary: Distribution of Trials of Colon / Colorectal Cancer by Affiliated Biomarkers
Figure 13.41 Clinical Trials Summary: Distribution of Trials of Head and Neck Cancer by Affiliated Biomarkers
Figure 14.1 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability
Figure 14.2 Biomarker-Driven Targeted Therapies: Distribution by Type of Molecule
Figure 14.3 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability and Type of Molecule
Figure 14.4 Biomarker-Driven Targeted Therapies: Distribution by Route of Administration
Figure 14.5 Leading Biomarker-Driven Targeted Therapies: Distribution by Number of Companion Diagnostic Products / Programs
Figure 14.6 Biomarker-Driven Targeted Therapy Developers: Distribution by Year of Establishment
Figure 14.7 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Size
Figure 14.8 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Ownership
Figure 14.9 Biomarker-Driven Targeted Therapy Developers: Distribution by Location of Headquarters
Figure 14.10 Leading Players: Distribution by Number of Biomarker-Driven Targeted Therapies
Figure 14.11 Heat Map Representation: Distribution by Company Size, Location of Headquarters and Commercial Availability of Therapy
Figure 15.1 Precision Medicine Software Solutions: Distribution by Type of Platform
Figure 15.2 Precision Medicine Software Solutions: Distribution by Purpose of Software Applications
Figure 15.3 Precision Medicine Software Solutions: Distribution by Type of Data Handled
Figure 15.4 Precision Medicine Software Solutions: Distribution by Therapeutic Area
Figure 15.5 Precision Medicine Software Solutions: Distribution by Type of End User
Figure 15.6 Precision Medicine Software Solution Developers: Distribution by Year of Establishment
Figure 15.7 Precision Medicine Software Solution Developers: Distribution by Company Size
Figure 15.8 Precision Medicine Software Solution Developers: Distribution by Location of Headquarters
Figure 15.9 World Map Representation: Distribution by Geography
Figure 16.1 Global Companion Diagnostics Development Services Market, 2022-2035 (USD Million)
Figure 16.2 Global Companion Diagnostics Development Services Market: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.3 Global Companion Diagnostics Development Services Market: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.4 Global Companion Diagnostics Development Services Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 16.5 Global Companion Diagnostics Development Services Market: Distribution by Region, 2022-2035 (USD Million)
Figure 16.6 Companion Diagnostics Development Services Market in North America, 2022-2035 (USD Million)
Figure 16.7 Companion Diagnostics Development Services Market in North America: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.8 Companion Diagnostics Development Services Market in North America: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.9 Companion Diagnostics Development Services Market in North America: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 16.7 Companion Diagnostics Development Services Market in Europe, 2022-2035 (USD Million)
Figure 16.8 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.9 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.10 Companion Diagnostics Development Services Market in Europe: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 16.11 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 16.12 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.13 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of The World: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.14 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 18.1 Concluding Remarks: Overall Market Landscape of Companion Diagnostics Service Providers
Figure 18.2 Concluding Remarks: Overall Market Landscape of Companion Diagnostics
Figure 18.3 Concluding Remarks: Partnerships and Collaborations
Figure 18.4 Concluding Remarks: Likely Partners
Figure 18.5 Concluding Remarks: Mergers and Acquisitions
Figure 18.6 Concluding Remarks: Big Pharma Initiatives
Figure 18.7 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 4.1 Companion Diagnostics Service Providers: List of Players
Table 4.2 Companion Diagnostics Service Providers: Information on Type of Service(s) Offered
Table 4.3 Companion Diagnostics Service Providers: Information on Type of Analytical Technique(s) Used
Table 4.4 Companion Diagnostics Service Providers: Information on Therapeutic Area(s)
Table 4.5 Companion Diagnostics Service Providers: Additional Information on Regulatory Certification(s) / Accreditation(s)
Table 6.1 Companion Diagnostics Service Providers: List of Companies Profiled
Table 6.2 Geneuity Clinical Research Services: Company Snapshot
Table 6.3 Geneuity Clinical Research Services: Companion Diagnostics Service Portfolio
Table 6.4 Geneuity Clinical Research Services: Recent Developments and Future Outlook
Table 6.5 Interpace Biosciences: Company Snapshot
Table 6.6 Interpace Biosciences: Companion Diagnostics Service Portfolio
Table 6.7 Interpace Biosciences: Recent Developments and Future Outlook
Table 6.8 Labcorp: Company Snapshot
Table 6.9 Labcorp: Companion Diagnostics Service Portfolio
Table 6.10 Labcorp: Recent Developments and Future Outlook
Table 6.11 ResearchDx: Company Snapshot
Table 6.12 ResearchDx: Companion Diagnostics Service Portfolio
Table 6.13 ResearchDx: Recent Developments and Future Outlook
Table 6.14 Quest Diagnostics: Company Snapshot
Table 6.15 Quest Diagnostics: Companion Diagnostics Service Portfolio
Table 6.16 Quest Diagnostics: Recent Developments and Future Outlook
Table 6.17 Q² Solutions: Company Snapshot
Table 6.18 Q² Solutions: Companion Diagnostics Service Portfolio
Table 6.19 Q² Solutions: Recent Developments and Future Outlook
Table 6.20 Almac Diagnostic Services: Company Snapshot
Table 6.21 Almac Diagnostic Services: Companion Diagnostics Service Portfolio
Table 6.22 Almac Diagnostic Services: Recent Developments and Future Outlook
Table 6.23 Biocartis: Company Snapshot
Table 6.24 Biocartis: Companion Diagnostics Service Portfolio
Table 6.25 Biocartis: Recent Developments and Future Outlook
Table 6.26 Cerba Research: Company Snapshot
Table 6.27 Cerba Research: Companion Diagnostics Service Portfolio
Table 6.28 Cerba Research: Recent Developments and Future Outlook
Table 6.29 Eurofins: Company Snapshot
Table 6.30 Eurofins: Companion Diagnostics Service Portfolio
Table 6.31 Eurofins: Recent Developments and Future Outlook
Table 6.32 MLM Medical Labs: Company Snapshot
Table 6.33 MLM Medical Labs: Companion Diagnostics Service Portfolio
Table 6.34 MLM Medical Labs: Recent Developments and Future Outlook
Table 6.35 QIAGEN: Company Snapshot
Table 6.36 QIAGEN: Companion Diagnostics Service Portfolio
Table 6.37 QIAGEN: Recent Developments and Future Outlook
Table 6.38 BGI Genomics: Company Snapshot
Table 6.39 BGI Genomics: Companion Diagnostics Service Portfolio
Table 6.40 BGI Genomics: Recent Developments and Future Outlook
Table 6.41 MEDx (Suzhou) Translational Medicine: Company Snapshot
Table 6.42 MEDx (Suzhou) Translational Medicine: Companion Diagnostics Service Portfolio
Table 6.43 MEDx (Suzhou) Translational Medicine: Recent Developments and Future Outlook
Table 6.44 MEDICAL & BIOLOGICAL LABORATORIES (MBL): Company Snapshot
Table 6.45 MEDICAL & BIOLOGICAL LABORATORIES (MBL): Companion Diagnostics Service Portfolio
Table 6.46 MEDICAL & BIOLOGICAL LABORATORIES (MBL): Recent Developments and Future Outlook
Table 6.47 Novogene: Company Snapshot
Table 6.48 Novogene: Companion Diagnostics Service Portfolio
Table 6.49 Novogene: Recent Developments and Future Outlook
Table 8.1 Companion Diagnostics Service Providers: List of Partnerships and Collaborations, 2017-2021
Table 9.1 Companies / Organizations Working on the Amyloid Beta Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.2 Companies / Organizations Working on the Tau Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.3 Companies / Organizations Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.4 Companies / Organizations Working on the HER Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.5 Companies / Organizations Working on the HR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.6 Companies / Organizations Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.7 Companies / Organizations Working on the BRAF Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.8 Companies / Organizations Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.9 Companies / Organizations Working on the KRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.10 Companies / Organizations Working on the MSI Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.11 Companies / Organizations Working on the NRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.12 Companies / Organizations Working on the CCR5 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.13 Companies / Organizations Working on the ALK Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.14 Companies / Organizations Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.15 Companies / Organizations Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.16 Companies / Organizations Working on the RET Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.17 Companies / Organizations Working on the ROS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.18 Companies / Organizations Working on the AST Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.19 Companies / Organizations Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.20 Companies / Organizations Working on the CA-125 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.21 Companies / Organizations Working on the AR-V7 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 10.1 Companion Diagnostics Service Providers: Mergers and Acquisitions, 2017-2021
Table 11.1 Comparison of Needs of Stakeholders
Table 13.1 List of Likely Drug Candidates / Potential Collaborators for Companion Diagnostic Developers
Table 13.2 List of Biomarkers across Moderately Popular Indications
Table 13.3 List of Biomarkers across Emerging Indications
Table 14.1 Biomarker Driven Targeted Therapies: Information on Commercial Availability, Type of Molecule and Route of Administration
Table 14.2 Biomarker Driven Targeted Therapies: List of Developers
Table 15.1 Precision Medicine Software Solutions: Information on Type of Platform, Status of Development and Compliance
Table 15.2 Precision Medicine Software Solutions: Information on Purpose of Software, Type of Data Handled, Therapeutic Area and End User
Table 15.3 Precision Medicine Software Solution Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 17.1 Genomenon: Company Snapshot
Table 17.2 Tymora Analytical Operations: Company Snapshot
Table 17.3 Novodiax: Company Snapshot
Table 17.4 OWL Metabolomics: Company Snapshot
Table 17.5 NeoGenomics Laboratories: Company Snapshot
Table 19.1 Companion Diagnostics Service Providers: Distribution by Year of Establishment
Table 19.2 Companion Diagnostics Service Providers: Distribution by Company Size
Table 19.3 Companion Diagnostics Service Providers: Distribution by Company Ownership
Table 19.4 Companion Diagnostics Service Providers: Distribution by Location of Headquarters
Table 19.5 World Map Representation: Distribution by Geography
Table 19.6 Companion Diagnostics Service Providers: Distribution by Service Offered
Table 19.7 Companion Diagnostics Service Providers: Distribution by Other Affiliated Service Offered
Table 19.8 Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
Table 19.9 Companion Diagnostics Service Providers: Distribution by Therapeutic Area
Table 19.10 Companion Diagnostics Service Providers: Distribution by Regulatory Accreditation / Certification
Table 19.11 Interpace Biosciences: Annual Revenues, FY 2016-Q3 2021 (USD Million)
Table 19.12 Labcorp Drug Development: Annual Revenues, FY 2016-2021 (USD Billion)
Table 19.13 Quest Diagnostics: Annual Revenues, FY 2016-2021 (USD Billion)
Table 19.14 Q² Solutions: Annual Revenues, FY 2016-2021 (USD Million)
Table 19.15 Almac Group Diagnostics: Annual Revenues, FY 2016-2021 (GBP Million)
Table 19.16 Biocartis: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Table 19.17 Eurofins: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Table 19.18 QIAGEN: Annual Revenues, FY 2016-2021 (USD Billion)
Table 19.19 Companion Diagnostics: Distribution by Assay Technique Used
Table 19.20 Companion Diagnostics: Distribution by Target Disease Indication
Table 19.21 Companion Diagnostics: Distribution by Therapeutic Area
Table 19.22 Companion Diagnostics: Distribution by Type of Biomarker Detected
Table 19.23 Companion Diagnostics: Distribution by Biochemical Nature of Biomarker Detected
Table 19.24 Companion Diagnostics: Distribution by Type of Sample Used
Table 19.25 Companion Diagnostics: Distribution by Commercial Availability and Therapeutic Area
Table 19.26 Companion Diagnostics: Distribution by Year of Initiation of Development of Investigational Programs
Table 19.27 Companion Diagnostics: Distribution by Year of Approval of Marketed Products
Table 19.28 Companion Diagnostics: Distribution by Regulatory Authority Involved in the Approval of Marketed Programs
Table 19.29 Companion Diagnostics: Distribution by Expediated Review Designation and Type of Biomarker Detected
Table 19.30 Companion Diagnostic Developers: Distribution by Year of Establishment
Table 19.31 Companion Diagnostic Developers: Distribution by Company Size
Table 19.32 Companion Diagnostic Developers: Distribution by Company Ownership
Table 19.33 Companion Diagnostic Developers: Distribution by Location of Headquarters
Table 19.34 World Map Representation: Distribution by Geography
Table 19.35 Most Active Players: Distribution by Number of Marketed Products and Investigational Programs
Table 19.36 Most Active Players: Distribution by Number of Marketed Products
Table 19.37 Most Active Players: Distribution by Number of Target Disease Indications
Table 19.38 Partnerships and Collaborations: Distribution by Year of Partnership
Table 19.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.40 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.41 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 19.42 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 19.43 Partnerships and Collaborations: Distribution by Type of Therapeutic Area
Table 19.44 Partnerships and Collaborations: Distribution by Year and Type of Partners
Table 19.45 Most Active Players: Distribution by Number of Partnerships
Table 19.46 Partnerships and Collaborations: Regional Distribution
Table 19.47 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 19.48 World Map Representation: Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials
Table 19.49 World Map Representation: Regional Distribution of Tau Biomarker Focused Clinical Trials
Table 19.50 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Table 19.51 World Map Representation: Regional Distribution of HER Biomarker Focused Clinical Trials
Table 19.52 World Map Representation: Regional Distribution of HR Biomarker Focused Clinical Trials
Table 19.53 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Table 19.54 World Map Representation: Regional Distribution of BRAF Biomarker Focused Clinical Trials
Table 19.55 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Table 19.56 World Map Representation: Regional Distribution of KRAS Biomarker Focused Clinical Trials
Table 19.57 World Map Representation: Regional Distribution of MSI Biomarker Focused Clinical Trials
Table 19.58 World Map Representation: Regional Distribution of NRAS Biomarker Focused Clinical Trials
Table 19.59 World Map Representation: Regional Distribution of CCR5 Biomarker Focused Clinical Trials
Table 19.60 World Map Representation: Regional Distribution of ALK Biomarker Focused Clinical Trials
Table 19.61 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Table 19.62 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Table 19.63 World Map Representation: Regional Distribution of RET Biomarker Focused Clinical Trials
Table 19.64 World Map Representation: Regional Distribution of ROS Biomarker Focused Clinical Trials
Table 19.65 World Map Representation: Regional Distribution of AST Biomarker Focused Clinical Trials
Table 19.66 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Table 19.67 World Map Representation: Regional Distribution of CA-125 Biomarker Focused Clinical Trials
Table 19.68 World Map Representation: Regional Distribution of AR-V7 Biomarker Focused Clinical Trials
Table 19.69 Mergers and Acquisitions: Distribution by Type of Deal
Table 19.70 Mergers and Acquisitions: Distribution by Year of Deal
Table 19.71 Mergers and Acquisitions: Regional Distribution
Table 19.72 Mergers and Acquisitions: Continent-wise Distribution
Table 19.73 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Table 19.74 Mergers and Acquisitions: Country-wise Distribution
Table 19.75 Mergers and Acquisitions: Distribution by Company Size
Table 19.76 Mergers and Acquisitions: Ownership Change Matrix
Table 19.77 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 19.78 Mergers and Acquisitions: Valuation by Acquisition Deal Multiples
Table 19.79 Key Players: Distribution by Number of Deals
Table 19.80 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 19.81 Clinical Trial Analysis: Distribution by Phase of Development
Table 19.82 Clinical Trial Analysis: Distribution by Sponsor
Table 19.83 Clinical Trial Analysis: Distribution by Recruitment Status
Table 19.84 Clinical Trial Analysis: Distribution by Therapy Design
Table 19.85 Clinical Trial Analysis: Distribution by Geography
Table 19.86 Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 19.87 Clinical Trial Analysis: Distribution by Most Popular Biomarkers
Table 19.88 Clinical Trial Analysis: Distribution by Moderately Popular Biomarkers
Table 19.89 Clinical Trial Analysis: Distribution by Less Popular / Preliminary Stage Biomarkers
Table 19.90 Other Emerging Biomarkers: Word Cloud
Table 19.91 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Trial Registration Year
Table 19.92 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Trial Registration Year
Table 19.93 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Trial Registration Year
Table 19.94 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Phase of Development
Table 19.95 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Phase of Development
Table 19.96 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Phase of Development
Table 19.97 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Sponsors
Table 19.98 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Sponsors
Table 19.99 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Sponsors
Table 19.100 Clinical Trial Analysis: Distribution of Trials for Most Popular Indications
Table 19.101 Clinical Trial Analysis: Distribution of Trials for Moderately Popular Indications
Table 19.102 Clinical Trial Analysis: Distribution of Trials for Less Popular and Other Indications
Table 19.103 Other Emerging Indications: Word Cloud
Table 19.104 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Trial Registration Year
Table 19.105 Clinical Trial Analysis: Distribution of Trial of Moderately Popular Indications by Trial Registration Year
Table 19.106 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Indications by Trial Registration Year
Table 19.107 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Phase of Development
Table 19.108 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Phase of Development
Table 19.109 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Phase of Development
Table 19.110 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Sponsor
Table 19.111 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Sponsor
Table 19.112 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Sponsor
Table 19.113 Clinical Trial Analysis: Distribution of Trials of Lung Cancer by Affiliated Biomarkers
Table 19.114 Clinical Trials Summary: Distribution of Trials of Breast Cancer by Affiliated Biomarkers
Table 19.115 Clinical Trials Summary: Distribution of Trials of Lymphoma by Affiliated Biomarkers
Table 19.116 Clinical Trials Summary: Distribution of Trials of Ovarian Cancer by Affiliated Biomarkers
Table 19.117 Clinical Trials Summary: Distribution of Trials of Prostate Cancer by Affiliated Biomarkers
Table 19.118 Clinical Trials Summary: Distribution of Trials of Melanoma by Affiliated Biomarkers
Table 19.119 Clinical Trials Summary: Distribution of Trials of Colon / Colorectal Cancer by Affiliated Biomarkers
Table 19.120 Clinical Trials Summary: Distribution of Trials of Head and Neck Cancer by Affiliated Biomarkers
Table 19.121 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability
Table 19.122 Biomarker-Driven Targeted Therapies: Distribution by Type of Molecule
Table 19.123 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability and Type of Molecule
Table 19.124 Biomarker-Driven Targeted Therapies: Distribution by Route of Administration
Table 19.125 Leading Biomarker-Driven Targeted Therapies: Distribution by Number of Companion Diagnostic Products / Programs
Table 19.126 Biomarker-Driven Targeted Therapy Developers: Distribution by Year of Establishment
Table 19.127 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Size
Table 19.128 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Ownership
Table 19.129 Biomarker-Driven Targeted Therapy Developers: Distribution by Location of Headquarters
Table 19.130 Leading Players: Distribution by Number of Biomarker-Driven Targeted Therapies
Table 19.131 Precision Medicine Software Solutions: Distribution by Type of Platform
Table 19.132 Precision Medicine Software Solutions: Distribution by Purpose of Software Applications
Table 19.133 Precision Medicine Software Solutions: Distribution by Type of Data Handled
Table 19.134 Precision Medicine Software Solutions: Distribution by Therapeutic Area
Table 19.135 Precision Medicine Software Solutions: Distribution by Type of End User
Table 19.136 Precision Medicine Software Solution Developers: Distribution by Year of Establishment
Table 19.137 Precision Medicine Software Solution Developers: Distribution by Company Size
Table 19.138 Precision Medicine Software Solution Developers: Distribution by Location of Headquarters
Table 19.139 World Map Representation: Distribution by Geography
Table 19.140 Global Companion Diagnostics Development Services Market, 2022-2035 (USD Million)
Table 19.141 Global Companion Diagnostics Development Services Market: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.142 Global Companion Diagnostics Development Services Market: Distribution by Type of Analytical Technique, 2022-2035 (USD Million)
Table 19.143 Global Companion Diagnostics Development Services Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 19.144 Global Companion Diagnostics Development Services Market: Distribution by Region, 2022-2035 (USD Million)
Table 19.145 Companion Diagnostics Development Services Market in North America, 2022-2035 (USD Million)
Table 19.146 Companion Diagnostics Development Services Market in North America: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.147 Companion Diagnostics Development Services Market in North America: Distribution by Type of Analytical Technique, 2022-2035 (USD Million)
Table 19.148 Companion Diagnostics Development Services Market in North America: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 19.149 Companion Diagnostics Development Services Market in Europe, 2022-2035 (USD Million)
Table 19.150 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.151 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Analytical Technique, 2022-2035 (USD Million)
Table 19.152 Companion Diagnostics Development Services Market in Europe: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 19.153 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Table 19.154 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.155 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of The World: Distribution by Type of Analytical Technique Offered, 2022-2035 (USD Million)
Table 19.156 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Source: www.sciencedirect.com/science/article/pii/S1936523321000553
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES